amiridine and Alcoholism

amiridine has been researched along with Alcoholism* in 1 studies

Trials

1 trial(s) available for amiridine and Alcoholism

Article	Year
[Efficacy of neuromidin in alcoholic encephalopathy]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2011, Volume: 111, Issue:3 40 patients with alcoholic encephalopathy, aged from 30 to 60 years, were enrolled in the study. Patients were divided into two groups: 20 patients in the treatment group received vasoactive, antioxidant treatment and neyromidin in dose 15 mg in solution during 10 days and then in tabs in dose 20 mg three times a day during 2 months. The comparison group included 20 patients receiving only vasoactive and antioxidant treatment. To the end of treatment, the positive changes in the state of patients reflected in the decrease in the number of complaints and neurological symptoms were seen in the treatment group. The significant improvement of MMSE scores, positive changes in P300 latency and amplitude, the increase in scores on physical activity scales, emotional functioning, mental health scales of SF-36 questionnaire were found as well. There were no serious treatment-emergent adverse events. Topics: Adult; Alcoholism; Aminoquinolines; Brain Diseases; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Treatment Outcome	2011

Article

Year

[Efficacy of neuromidin in alcoholic encephalopathy].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2011, Volume: 111, Issue:3

40 patients with alcoholic encephalopathy, aged from 30 to 60 years, were enrolled in the study. Patients were divided into two groups: 20 patients in the treatment group received vasoactive, antioxidant treatment and neyromidin in dose 15 mg in solution during 10 days and then in tabs in dose 20 mg three times a day during 2 months. The comparison group included 20 patients receiving only vasoactive and antioxidant treatment. To the end of treatment, the positive changes in the state of patients reflected in the decrease in the number of complaints and neurological symptoms were seen in the treatment group. The significant improvement of MMSE scores, positive changes in P300 latency and amplitude, the increase in scores on physical activity scales, emotional functioning, mental health scales of SF-36 questionnaire were found as well. There were no serious treatment-emergent adverse events.

Topics: Adult; Alcoholism; Aminoquinolines; Brain Diseases; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Treatment Outcome

2011